EpiVax, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research

EpiVax, Inc. - Product Pipeline Review - 2016

EpiVax, Inc. - Product Pipeline Review - 2016 - Global Markets Direct - Market Research
EpiVax, Inc. - Product Pipeline Review - 2016
Published Jun 30, 2016
36 pages — Published Jun 30, 2016
Price US$ 1,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, EpiVax, Inc. - Product Pipeline Review - 2016, provides an overview of the EpiVax, Inc.s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by EpiVax, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of EpiVax, Inc.
- The report provides overview of EpiVax, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses EpiVax, Inc.s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features EpiVax, Inc.s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate EpiVax, Inc.s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for EpiVax, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding EpiVax, Inc.s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  
Source:
Document ID
GMDHC08076CDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
EpiVax, Inc. Snapshot51
  EpiVax, Inc. Overview51
  Key Information51
  Key Facts51
EpiVax, Inc. Research and Development Overview63
  Key Therapeutic Areas63
EpiVax, Inc. Pipeline Review92
  Pipeline Products by Stage of Development91
  Pipeline Products Monotherapy101
EpiVax, Inc. Pipeline Products Glance112
  EpiVax, Inc. Early Stage Pipeline Products111
    Preclinical Products/Combination Treatment Modalities111
    Discovery Products/Combination Treatment Modalities121
EpiVax, Inc. Drug Profiles1314
  Deimmunized FVIII131
    Product Description131
    Mechanism of Action131
    R&D Progress131
  Epi-13141
    Product Description141
    Mechanism of Action141
    R&D Progress142
  Helicobacter pylori vaccine161
    Product Description161
    Mechanism of Action161
    R&D Progress161
  influenza [strain H1N1] vaccine171
    Product Description171
    Mechanism of Action171
    R&D Progress171
  onabotulinumtoxin A181
    Product Description181
    Mechanism of Action181
    R&D Progress181
  smallpox vaccine191
    Product Description191
    Mechanism of Action191
    R&D Progress191
  Synthetic Peptides for Allergy201
    Product Description201
    Mechanism of Action201
    R&D Progress201
  Synthetic Peptides for Pompe disease211
    Product Description211
    Mechanism of Action211
    R&D Progress211
  tuberculosis vaccine221
    Product Description221
    Mechanism of Action221
    R&D Progress221
  tularaemia vaccine231
    Product Description231
    Mechanism of Action231
    R&D Progress231
  equine encephalitis vaccine241
    Product Description241
    Mechanism of Action241
    R&D Progress241
  HIV vaccine251
    Product Description251
    Mechanism of Action251
    R&D Progress251
  influenza [strain A/H7N9] vaccine261
    Product Description261
    Mechanism of Action261
    R&D Progress261
EpiVax, Inc. Pipeline Analysis274
  EpiVax, Inc. Pipeline Products by Target271
  EpiVax, Inc. Pipeline Products by Route of Administration281
  EpiVax, Inc. Pipeline Products by Molecule Type291
  EpiVax, Inc. Pipeline Products by Mechanism of Action301
EpiVax, Inc. Recent Pipeline Updates311
EpiVax, Inc. Dormant Projects321
EpiVax, Inc. Company Statement331
EpiVax, Inc. Locations And Subsidiaries341
  Head Office341
Appendix352
  Methodology351
  Coverage351
  Secondary Research351
  Primary Research351
  Expert Panel Validation351
  Contact Us351
  Disclaimer361

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "EpiVax, Inc. - Product Pipeline Review - 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/EpiVax-Inc-Product-Pipeline-Review-2016-2088-16067>
  
APA:
Global Markets Direct - Market Research. (2016). EpiVax, Inc. - Product Pipeline Review - 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/EpiVax-Inc-Product-Pipeline-Review-2016-2088-16067>
  
US$ 1,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.